Myocardial necrosis marker increased
(UMLS:C3854443)
- UMLS ID:
- C3854443
- MeSH ID:
- N/A
Synonym(s)
1.
Myocardial necrosis marker increased
Associated Drug(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Atorvastatin | FAERS: 34 | US FAERS | |
| 2 | Clozapine | FAERS: 6 Canada Vigilance: 8 | Canada Vigilance US FAERS | |
| 3 | Ticagrelor | FAERS: 6 | US FAERS | |
| 4 | Risperidone | FAERS: 5 | US FAERS | |
| 5 | Sunitinib | FAERS: 5 | US FAERS | |
| 6 | Crizotinib | FAERS: 4 | US FAERS | |
| 7 | Hydroxychloroquine | FAERS: 4 | US FAERS | |
| 8 | Lenalidomide | FAERS: 4 | US FAERS | |
| 9 | teriflunomide | FAERS: 4 | US FAERS | |
| 10 | Fluvastatin | FAERS: 3 | US FAERS | |
| 11 | Octreotide | FAERS: 3 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 12 | Telbivudine | FAERS: 3 | US FAERS | |
| 13 | Varenicline | FAERS: 3 | US FAERS | |
| 14 | treprostinil | FAERS: 3 | US FAERS | |
| 15 | Baclofen | FAERS: 2 | US FAERS | |
| 16 | Epoprostenol | FAERS: 2 | US FAERS | |
| 17 | Insulin Glargine | FAERS: 2 | US FAERS | |
| 18 | LCZ 696 | FAERS: 2 | US FAERS | |
| 19 | Lamivudine | FAERS: 2 | US FAERS | |
| 20 | Mebendazole | FAERS: 2 | US FAERS | |
| 21 | PCI 32765 | FAERS: 2 | US FAERS | |
| 22 | Propranolol | FAERS: 2 | US FAERS | |
| 23 | Rosiglitazone | FAERS: 2 | US FAERS | |
| 24 | Simvastatin | FAERS: 2 | US FAERS | |
| 25 | Voriconazole | FAERS: 2 | US FAERS | |
| 26 | ambrisentan | FAERS: 2 | US FAERS | |
| 27 | gadobutrol | FAERS: 2 | US FAERS | |
| 28 | pimavanserin | FAERS: 2 | US FAERS | |
| 29 | 4-hydroxybutyric acid | FAERS: 1 | US FAERS | |
| 30 | 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide | FAERS: 1 | US FAERS | |
| 31 | Acyclovir | FAERS: 1 | US FAERS | |
| 32 | Allopurinol | FAERS: 1 | US FAERS | |
| 33 | CH5424802 | FAERS: 1 | US FAERS | |
| 34 | Clarithromycin | FAERS: 1 | US FAERS | |
| 35 | Dabigatran | FAERS: 1 | US FAERS | |
| 36 | Dimethyl Fumarate | FAERS: 1 | US FAERS | |
| 37 | Droxidopa | FAERS: 1 | US FAERS | |
| 38 | Duloxetine Hydrochloride | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 39 | Epinephrine | FAERS: 1 | US FAERS | |
| 40 | Fingolimod Hydrochloride | FAERS: 1 | US FAERS | |
| 41 | Fractals | FAERS: 1 | US FAERS | |
| 42 | Ganciclovir | FAERS: 1 | US FAERS | |
| 43 | Imatinib Mesylate | FAERS: 1 | US FAERS | |
| 44 | Iopamidol | FAERS: 1 | US FAERS | |
| 45 | Levetiracetam | FAERS: 1 | US FAERS | |
| 46 | Lisdexamfetamine Dimesylate | FAERS: 1 | US FAERS | |
| 47 | Morphine | FAERS: 1 | US FAERS | |
| 48 | Naproxen | FAERS: 1 | US FAERS | |
| 49 | Phentermine | FAERS: 1 | US FAERS | |
| 50 | Prednisone | FAERS: 1 | US FAERS | |
| 51 | Pregabalin | FAERS: 1 | US FAERS | |
| 52 | Propranolol | FAERS: 1 | US FAERS | |
| 53 | Rivastigmine | FAERS: 1 | US FAERS | |
| 54 | Rosuvastatin Calcium | FAERS: 1 | US FAERS | |
| 55 | Sorafenib | FAERS: 1 | US FAERS | |
| 56 | Sulfamethoxazole | FAERS: 1 | US FAERS | |
| 57 | Tenofovir | FAERS: 1 | US FAERS | |
| 58 | Thyroxine | FAERS: 1 | US FAERS | |
| 59 | Travoprost | FAERS: 1 | US FAERS | |
| 60 | Valproic Acid | FAERS: 1 | US FAERS | |
| 61 | bosutinib | FAERS: 1 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 62 | eltrombopag | FAERS: 1 | US FAERS | |
| 63 | entecavir | FAERS: 1 | US FAERS | |
| 64 | lenvatinib | FAERS: 1 | US FAERS | |
| 65 | mirabegron | FAERS: 1 | US FAERS | |
| 66 | palbociclib | FAERS: 1 | US FAERS | |
| 67 | pazopanib | FAERS: 1 | US FAERS | |
| 68 | treprostinil | FAERS: 1 | US FAERS | |
| 69 | Celecoxib | Canada Vigilance: 1 | Canada Vigilance | |
| 70 | Chloroquine | Canada Vigilance: 1 | Canada Vigilance | |
| 71 | Hydroxychloroquine | Canada Vigilance: 4 | Canada Vigilance | |
| 72 | Tacrolimus | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.